LUND, Sweden, April 17, 2018 /PRNewswire/ — NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today announced that the last visit of the last healthy volunteer in the clinical phase I single…

Source: https://www.prnewswire.com/news-releases/neurovives-partner-yungjin-pharm-completes-kl1333-phase-i-study-recruitment-300631003.html

This entry was posted on Tuesday, April 17th, 2018 at 1:50 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.